J Lai1, Z Dememew2, D Jerene3, A Abashawl4, B Feleke5, A M Teklu6, A Ruff4. 1. Johns Hopkins University Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland. 2. Johns Hopkins University Technical Support for Ethiopian HIV/AIDS Initiative, Addis Ababa, Management Sciences for Health, Addis Ababa, Ethiopia. 3. Johns Hopkins University Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, Johns Hopkins University Technical Support for Ethiopian HIV/AIDS Initiative, Addis Ababa, Management Sciences for Health, Addis Ababa, Ethiopia. 4. Johns Hopkins University Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, Johns Hopkins University Technical Support for Ethiopian HIV/AIDS Initiative, Addis Ababa. 5. Ethiopia Centers for Disease Prevention and Control, Addis Ababa. 6. Johns Hopkins University Technical Support for Ethiopian HIV/AIDS Initiative, Addis Ababa.
Abstract
SETTING: Sixty-seven government health facilities providing tuberculosis (TB) and human immunodeficiency virus (HIV) services across Ethiopia. OBJECTIVE: To examine clinician barriers to implementing isoniazid preventive therapy (IPT) among people living with HIV. DESIGN: A cross-sectional study to evaluate the provider-related factors associated with high IPT coverage at the facility level. RESULTS: On bivariate analysis, the odds of high IPT implementation were lower when clinicians felt patients were negatively affected by the side effects of IPT (OR 0.18, 95%CI 0.04-0.81) and perceived that IPT increased multidrug-resistant TB (MDR-TB) rates (OR 0.66, 95%CI 0.44-0.98). The presence of IPT guidelines on site (OR 2.93, 95%CI 1.10-7.77) and TB-HIV training (OR 3.08, 95%CI 1.11-8.53) had a positive relationship with high IPT uptake. In the multivariate model, clinician's perception that active TB was difficult to rule out had a negative association with a high IPT rate (OR 0.93; 95%CI 0.90-0.95). CONCLUSIONS: Clinician impression that ruling out active TB among HIV patients is difficult was found to be a significant barrier to IPT uptake. Continued advancement of IPT relies greatly on improving the ability of providers to determine IPT eligibility and more confidently care for patients on IPT. Improved clinician support and training as well as development of new TB diagnostic technologies could impact IPT utilization among providers.
SETTING: Sixty-seven government health facilities providing tuberculosis (TB) and human immunodeficiency virus (HIV) services across Ethiopia. OBJECTIVE: To examine clinician barriers to implementing isoniazid preventive therapy (IPT) among people living with HIV. DESIGN: A cross-sectional study to evaluate the provider-related factors associated with high IPT coverage at the facility level. RESULTS: On bivariate analysis, the odds of high IPT implementation were lower when clinicians felt patients were negatively affected by the side effects of IPT (OR 0.18, 95%CI 0.04-0.81) and perceived that IPT increased multidrug-resistant TB (MDR-TB) rates (OR 0.66, 95%CI 0.44-0.98). The presence of IPT guidelines on site (OR 2.93, 95%CI 1.10-7.77) and TB-HIV training (OR 3.08, 95%CI 1.11-8.53) had a positive relationship with high IPT uptake. In the multivariate model, clinician's perception that active TB was difficult to rule out had a negative association with a high IPT rate (OR 0.93; 95%CI 0.90-0.95). CONCLUSIONS: Clinician impression that ruling out active TB among HIVpatients is difficult was found to be a significant barrier to IPT uptake. Continued advancement of IPT relies greatly on improving the ability of providers to determine IPT eligibility and more confidently care for patients on IPT. Improved clinician support and training as well as development of new TB diagnostic technologies could impact IPT utilization among providers.
Authors: Faiz Ahmad Khan; Sabine Verkuijl; Andrew Parrish; Fadzai Chikwava; Raphael Ntumy; Wafaa El-Sadr; Andrea A Howard Journal: AIDS Date: 2014-06-19 Impact factor: 4.177
Authors: Sylvia M LaCourse; Lisa M Cranmer; Daniel Matemo; John Kinuthia; Barbra A Richardson; Grace John-Stewart; David J Horne Journal: J Acquir Immune Defic Syndr Date: 2016-02-01 Impact factor: 3.731
Authors: Jonathan E Golub; Valeria Saraceni; Solange C Cavalcante; Antonio G Pacheco; Lawrence H Moulton; Bonnie S King; Anne Efron; Richard D Moore; Richard E Chaisson; Betina Durovni Journal: AIDS Date: 2007-07-11 Impact factor: 4.177
Authors: Haileyesus Getahun; Wanitchaya Kittikraisak; Charles M Heilig; Elizabeth L Corbett; Helen Ayles; Kevin P Cain; Alison D Grant; Gavin J Churchyard; Michael Kimerling; Sarita Shah; Stephen D Lawn; Robin Wood; Gary Maartens; Reuben Granich; Anand A Date; Jay K Varma Journal: PLoS Med Date: 2011-01-18 Impact factor: 11.069
Authors: G Caturegli; J Materi; A Lombardo; M Milovanovic; N Yende; E Variava; J E Golub; N A Martinson; C J Hoffmann Journal: Public Health Action Date: 2020-09-21